P-转移因子联合酮替芬降低毛细支气管炎后支气管哮喘患病率的研究  

P-Transfer factor oral solution combined with Ketotifen decreased the incidence of asthma following bronchiolitis

作　　者：黄英[1] 张儒谊[1] 李渠北[1] 何佳敏[1] 

机构地区：[1]重庆医科大学儿童医院呼吸科,重庆400014

出　　处：《重庆医科大学学报》2002年第1期74-75,78,共3页Journal of Chongqing Medical University

摘　　要：目的：观察Ｐ－转移因子和酮替芬联合应用能否降低毛细支气管炎后支气管哮喘患病率。方法：５０例毛细支气管炎患儿采用口服Ｐ－转移因子进行免疫调节治疗并辅以酮替芬抗过敏，疗程３～６个月，临床随访≥１年，观察发生哮喘的例数。同时检测防治前后患儿血清ＩｇＥ、ＩｇＧ、ＩｇＡ、ＩｇＭ与Ｔ细胞亚群变化。４６例毛细支气管炎患儿不用药作为对照组。结果：完成随访　＞１年者，防治组４３例中仅２例（４．６５　％）发生哮喘，而对照组３９例中有１１例（２８．２１％）发生哮喘，两组有显著差异（Ｐ　＜０．０１）。防治组患儿免疫功能改善明显，ＩｇＥ水平，ＣＤ４／ＣＤ８比率下降，ＩｇＧ、ＩｇＡ、ＣＤ３水平增高，与防治前相比差异有显著性。结论：Ｐ　－转移因子联合酮替芬口服，可降低毛细支气管炎后支气管哮喘患病率。Objective: To evaluate the efficiency of P-transfer factor oral solution (P-TFO) combined with ketotifen (KTF) in decreasing the incidence of asthma following bronchiolitis. Methods: 50 patients with bronchiolitis were given P-TFO and KTF compared with 46 patients with bronchiolitis without the treatment of P-TFO and KTF. The total course was 3～6 months and the average time of follow up was 1 year. Serum level of IgE, IgG, IgA, IgM and T lymphocyte subsets were tested before and after the treatment. Results: After follow up over 1 year, 2/46 (4.65%) of the patients with bronchiolitis receiving P-TFO and KTF developed asthma compared with 11/39 (28.21%) of the controls with bronchiolitis (P <0.01). The immune function of the patients with bronchiolitis receiving P-TFO and KTF improved. The serum level of IgE and the ratio of CD4/CD8 decreased, and the CD3,CD8 counts were increased after the treatment. Conclusion: P-TFO combined with KTF is an effective way to decrease the incidence of asthma following bronchiolitis.

关 键 词：毛细支气管炎 P-转移因子 酮替芬 哮喘 防治 

分 类 号：R562.250.1[医药卫生—呼吸系统] R562.110.7[医药卫生—内科学]